BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that the company is moving its conference call that was scheduled for 5:00 p.m. ET today to 8:00 a.m. ET tomorrow morning. The company’s Prescription Drug User Fee Act (PDUFA) target action date for its supplemental new drug application for Auryxia is today, November 6, 2017. As of the time of this press release, the company has not received a response from the FDA. As such, Keryx has decided to move its third quarter financial results call to tomorrow.
To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619. The call will be webcast live and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia® (ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contacts:
Amy Sullivan
SVP, Corporate Affairs
T: 617-466-3519
Amy.sullivan@keryx.com
Lora Pike
Senior Director, Investor Relations & Corporate Communications
T: 617.466.3511
lora.pike@keryx.com